{
    "clinical_study": {
        "@rank": "149536", 
        "arm_group": {
            "arm_group_label": "No treatment"
        }, 
        "brief_summary": {
            "textblock": "Primary objective:\n\n      Characterize the natural history of MoCD type A in terms of survival\n\n      Secondary objectives:\n\n        1. Evaluate blood and urine for biochemical markers\n\n        2. Evaluate head circumference, seizure activity and neurologic outcomes\n\n        3. To evaluate brain MRI\n\n        4. Compare blood and urine analysis, head circumference, seizure activity and neurologic\n           outcomes to MRI findings"
        }, 
        "brief_title": "A Natural History Study of Molybdenum Cofactor and Isolated Sulfite Oxidase Deficiencies", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Molybdenum Cofactor and Isolated Sulfite Oxidase Deficiencies", 
        "condition_browse": {
            "mesh_term": "Amino Acid Metabolism, Inborn Errors"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Both living and deceased patients of any age will be considered for study inclusion.\n\n          2. Diagnosis of MoCD or isolated SOX deficiency\n\n          3. Documented informed consent\n\n        Exclusion Criteria:\n\n        1. MoCD Type A patient who was in Study ALX-MCD-501"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The actual sample size will depend on successful identification of patients with MoCD or\n        isolated SOX deficiency"
            }
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01735188", 
            "org_study_id": "ALX-MCD-502", 
            "secondary_id": "ALX-MCD-502"
        }, 
        "intervention": {
            "arm_group_label": "No treatment", 
            "intervention_name": "No treatment", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": "Molybdenum"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Natural history study", 
        "lastchanged_date": "December 3, 2013", 
        "location": [
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals (Sponsor)"
                }, 
                "facility": {
                    "address": {
                        "city": "Woodinville", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98072"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals (Sponsor)"
                }, 
                "facility": {
                    "address": {
                        "city": "Haifa", 
                        "country": "Israel", 
                        "zip": "31096"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals (Sponsor)"
                }, 
                "facility": {
                    "address": {
                        "city": "Badalona", 
                        "country": "Spain", 
                        "state": "Catalonia", 
                        "zip": "08916"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals (Sponsor)"
                }, 
                "facility": {
                    "address": {
                        "city": "Esplugues de Llobregat", 
                        "country": "Spain", 
                        "zip": "08950"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals (Sponsor)"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals (Sponsor)"
                }, 
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "zip": "41013"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals (Sponsor)"
                }, 
                "facility": {
                    "address": {
                        "city": "Ankara", 
                        "country": "Turkey", 
                        "zip": "06100"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals (Sponsor)"
                }, 
                "facility": {
                    "address": {
                        "city": "Kayseri", 
                        "country": "Turkey", 
                        "zip": "38010"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Israel", 
                "Spain", 
                "Turkey"
            ]
        }, 
        "number_of_groups": "1", 
        "official_title": "A NATURAL HISTORY STUDY OF MOLYBDENUM COFACTOR AND ISOLATED SULFITE OXIDASE DEFICIENCIES", 
        "overall_contact": {
            "email": "clinicaltrials@alxn.com", 
            "last_name": "Alexion Pharmaceuticals (Sponsor)"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: National Health Service (West of Scotland Research Ethics Service)"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To characterize the natural history of molybdenum cofactor deficiency (MoCD) type A, the most common subtype of MoCD, in terms of survival", 
            "safety_issue": "No", 
            "time_frame": "September 2014"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01735188"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "To evaluate levels of the biochemical markers S-sulfocysteine (SSC), uric acid, and xanthine in blood, urine, and cerebral spinal fluid over time in patients with MoCD and isolated sulfite oxidase (SOX) deficiency.", 
            "safety_issue": "No", 
            "time_frame": "September 2014"
        }, 
        "source": "Alexion Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alexion Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "N/A", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}